Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for GVHD prophylaxis in older sibling allogeneic HSCT
ChiCTR2300072481Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib in hematopoietic malignancies, Acute Leukaemia, chronic myelogenous leukemia (CML) and 2 more (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: acute graft-versus-host disease. Started Jul 2022; status: recruiting.
02
Drugs
03
Conditions
hematopoietic malignanciesAcute Leukaemiachronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2300072481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072481.